|
1. Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis current view and future perspective on lipoprotein modification treatment. Neth Heart J 2017;25:231-42. doi. 10.1007/s12471-017-0959-2 2. Back M, Yurdagul A, Tabas I, Oorni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol2019;16:389-406. doi. 10.1038/s41569-019-0169-2 3. Tabor CM, Shaw CA, Robertson S, Miller MR, Duffin R, Donaldson K, et al. Platelet activation independent of pulmonary inflammation contributes to diesel exhaust particulate-induced promotion of arterial thrombosis. Part Fibre Toxicol 2016;13:6-. doi. 10.1186/s12989-016-0116-x 4. Stemme S, Rymo L, Hansson G. Polyclonal origin of T lymphocytes in human atherosclerotic plaques. Lab Invest J Technical Meth Pathol1991;65:654. 5. Lievens D, Habets KL, Robertson AK, Laouar Y, Winkels H, Rademakers T, et al. Abrogated transforming growth factor beta receptor II signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. European Heart J2013;34:3717-27. doi.10.1093/eurheartj/ehs106 6. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets exacerbate atherosclerosis in Mice deficient in apolipoprotein E. Nature Med2003;9:61-7. doi.10.1038/nm810 7. Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. Platelet to lymphocyte ratio a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. Plos One 2013;8: 67688. doi.10.1371/journal.pone.0067688 8. Yildiz A, Yuksel M, Oylumlu M, Polat N, Akyuz A, Acet H, et al. The utility of the platelet lymphocyte ratio for predicting no reflow in patients with ST segment elevation myocardial infarction. Clin Appl Throm Hem 2015;21:223-8. 9. Oylumlu M, Yıldız A, Oylumlu M, Yuksel M, Polat N, Bilik MZ, et al. Platelet to lymphocyte ratio is a predictor of in hospital mortality patients with acute coronary syndrome. Anatol J Cardiol 2015;15:277. doi.10.5152/akd.2014.5366 10. Temiz A, Gazi E, Gungor O, Barutçu A, Altun B, Bekler A, et al. Platelet lymphocyte ratio and risk of in hospital mortality in patients with ST elevated myocardial infarction. Int Med J Exp Clin Res 2014;20:660. 11. ozcancetin EH, Cetin MS, Aras D, Topaloglu S, Temizhan A, Kisacik HL, et al. Platelet to lymphocyte ratio as a prognostic marker of in hospital and long term major adverse cardiovascular events in ST segment elevation myocardial infarction. Angiology 2016;67336-45. doi. 10.1177/0003319715591751 12. Yuksel M, Yıldız A, Oylumlu M, Akyuz A, Aydın M, Kaya H, et al. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatolian J Cardiol 2016;15:640. 13. Sari I, Sunbul M, Mammadov C, Durmus E, Bozbay M, Kivrak T, et al. Relation of neutrophil to lymphocyte and platelet to lymphocyte ratio with coronary artery disease severity in patients undergoing coronary angiography. Kardiol Pol Heart J2015;73:1310-6. 14. Yayla C, Akboga MK, Canpolat U, Akyel A, Yayla KG, Dogan M, et al. Platelet to lymphocyte ratio can be a predictor of infarct related artery patency in patients with ST segment elevation myocardial infarction. Angiology 2015;66:831-6. 15. Bekler A, Gazi E, Yılmaz M, Temiz A, Altun B, Barutcu A, et al. Could elevated platelet lymphocyte ratio predict left ventricular systolic dysfunction in patients with non ST elevated acute coronary syndrome? Anatol J Cardiol2015;15:385. doi.10.5152/akd.2014.5434 16. Kurtul A, Yarlioglues M, Murat SN, Ergun G, Duran M, Kasapkara HA, et al. Usefulness of the platelet to lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction. Am J Cardiol2014;114:342-7. doi.10.1016/j.amjcard.2014.04.045
|
